# US 2012/0251613 A1 · Method for treating vitiligo with a prostaglandin analogue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251613 A1
- Document ID: US20120251613A1
- Status: Published application
- Kind: A1
- Application number: 13/194,458
- Filed: 2011-07-29
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Assignees: Agila Specialities Pvt. Ltd.
- Inventors: Rajeev JAIN; Tarun Narang; Satya Srinivas Chetlapalli
- Web page: https://patentgrep.com/patent/US20120251613A1

## CPC

- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of stimulating melanogenesis in a skin surface of a patient, by treating the skin surface with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier. The topical formulation may be a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch. The dermatologically acceptable carrier may contain an oily carrier or an aqueous carrier.

## Claims

### Claim 1

1) A method of stimulating pigmentation in a depigmented skin region of a patient, comprising treating said depigmented skin region with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier,
said depigmented skin region having fewer melanocytes per square centimeter than a nondepigmented skin region of said patient, said depigmented skin region being surrounded by or adjacent to said nondepigmented skin region.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein said depigmented skin region has no melanocytes.

### Claim 3 (depends on 1)

3) The method of claim 1, wherein said topical formulation is a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, or a transdermal patch.

### Claim 4 (depends on 1)

4) The method of claim 1, wherein the dermatologically acceptable carrier is an oily carrier.

### Claim 5 (depends on 1)

5) The method of claim 1, wherein the dermatologically acceptable carrier is an aqueous carrier.

### Claim 6 (depends on 5)

6) The method of claim 5, wherein the carrier further comprises liposomes or micelles.

### Claim 7 (depends on 5)

7) The method of claim 5, wherein the carrier has a pH of between about 4 and about 10.

### Claim 8 (depends on 7)

8) The method of claim 7, wherein the carrier comprises a buffer.

### Claim 9 (depends on 1)

9) The method of claim 1, wherein the carrier comprises an emulsion, said emulsion comprising:
an oil phase containing bimatoprost in an amount of from about 0.01% to about 25% by weight of the formulation, dissolved or dispersed within an oil- or wax-based formulation; and
an aqueous phase containing water and an optional solvent selected from the group consisting of lower alcohols, lower glycols, and glycerin;
said emulsion being selected from the group consisting of an oil-in-water emulsion and a water-in-oil emulsion.

### Claim 9

9) A method of treating a patient suffering from segmental or focal vitiligo, comprising treating a depigmented skin surface of said patient with a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said treating step being carried out at regular intervals until repigmentation of said depigmented skin surface is complete.

### Claim 10

10) A method of treating a patient suffering from generalized vitiligo, comprising a first step of treating a depigmented skin surface of said patient with a topical formulation comprising a first amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said first amount being effective to promote repigmentation, wherein said first step is carried out at regular intervals until repigmentation of said depigmented skin surface is complete.

### Claim 11 (depends on 10)

11) The method of claim 10, wherein said method further comprises a second step of treating a depigmented skin surface of said patient with a topical formulation comprising a second amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier,
said second amount being less than said first amount and effective to maintain pigmentation.

### Claim 12

12) A method of treating localized skin depigmentation in a patient, comprising treating depigmented skin of said patient by applying thereto a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier.

### Claim 13 (depends on 12)

13) The method of claim 12, wherein said patient suffers from vitiligo.

### Claim 14 (depends on 12)

14) The method of claim 12, wherein said patient suffers from a condition selected from the group consisting of generalized vitiligo, acrofacial vitiligo, localized vitiligo, and segmental vitiligo.

### Claim 15 (depends on 12)

15) The method of claim 12, wherein said topical formulation is selected from the group consisting of a cream, a gel, a lotion, a spray, an ointment, an aqueous solution, a nonaqueous solution, and a transdermal patch.

### Claim 16 (depends on 12)

16) The method of claim 12, wherein the dermatologically acceptable carrier is an aqueous carrier.

### Claim 17 (depends on 16)

17) The method of claim 16, wherein the carrier further comprises liposomes or micelles.

### Claim 18 (depends on 16)

18) The method of claim 16, wherein the carrier has a pH of between about 4 and about 10.

### Claim 19 (depends on 16)

19) The method of claim 16, comprising treating said patient with a topical formulation comprising about 0.01% to about 0.03% by weight of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in an aqueous carrier.

### Claim 20 (depends on 12)

20) The method of claim 12, comprising treating said patient with a topical formulation comprising about 0.01% to about 0.03% by weight of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in an aqueous carrier, said formulation being administered in an amount of from about 0.02 mL to about 0.05 mL per 2 cm2 of skin surface.

### Claim 21

21) A method of treating a patient suffering from vitiliginous lesions on the face, the neck, or both the face and the neck, said method comprising:
treating said lesions with a topical formulation comprising a first amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier, said first amount being effective to promote repigmentation of said lesions;
wherein said treating step is carried out at regular intervals until repigmentation of said lesions is complete.

### Claim 22

22) A method of treating localized skin depigmentation in a patient, comprising treating depigmented skin of said patient by applying thereto a topical formulation comprising an effective amount of 17-phenyl-18,19,20-trinor-PGF2α ethyl amide in a dermatologically acceptable carrier;
said method further comprising a step of treating said depigmented skin with a composition selected from the group consisting of pseudocatalase cream, dermabest gel, V-Tar, tacrolimus, pimecrolimus, steroids, psoralen, methoxsalen, trioxsalen, glatiramer acetate, and topical calcineurin inhibitors.
